Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Hepatocellular 7Neuroendocrine Tumors 2Neoplasm Metastasis 2Colorectal Neoplasms 2Colonic Neoplasms 2Cholangiocarcinoma 2Sarcoma 1Recurrence 1Rectal Neoplasms 1Ovarian Neoplasms 1Liver Neoplasms 1Liver Malignancy 1Hepatic Malignancies 1Carcinoma, Ovarian Epithelial 1Bile Duct Neoplasms 1

Interventions

Cyclophosphamide 151Dexamethasone 140Rituximab 83fludarabine 78Cytarabine 69Lenalidomide 68Bortezomib 63fludarabine phosphate 62Gemcitabine 62venetoclax 54Etoposide 53pembrolizumab 52pomalidomide 48Paclitaxel 48Cisplatin 47Carboplatin 47Peripheral Blood Stem Cell Transplantation 46Filgrastim 40Radiotherapy 39Calcium Dobesilate 36Busulfan 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 29Vincristine 28Temozolomide 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Recurrence × Yttrium-90 × Clear all
NCT01898962 2013-07-15

Definitive Therapy for Oligometastatic Solid Malignancies

Rocky Mountain Cancer Centers

Phase 2 Unknown
110 enrolled
Sarcoma

Neoplasm Metastasis, Recurrence, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡